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Abstract
Background: Meningitis is the inflammation of the meninges in response to infection or chemical agents. While
aseptic meningitis, most frequently caused by enteroviruses, is usually benign with a self-limiting course, bacterial
meningitis remains associated with high morbidity and mortality rates, despite advances in antimicrobial therapy
and intensive care. Fast and accurate differential diagnosis is crucial for assertive choice of the appropriate
therapeutic approach for each form of meningitis.
Methods: We used 2D-PAGE and mass spectrometry to identify the cerebrospinal fluid proteome specifically
related to the host response to pneumococcal, meningococcal, and enteroviral meningitis. The disease-specific
proteome signatures were inspected by pathway analysis.
Results: Unique cerebrospinal fluid proteome signatures were found to the three aetiological forms of meningitis
investigated, and a qualitative predictive model with four protein markers was developed for the differential
diagnosis of these diseases. Nevertheless, pathway analysis of the disease-specific proteomes unveiled that
Kallikrein-kinin system may play a crucial role in the pathophysiological mechanisms leading to brain damage in
bacterial meningitis. Proteins taking part in this cellular process are proposed as putative targets to novel
adjunctive therapies.
Conclusions: Comparative proteomics of cerebrospinal fluid disclosed candidate biomarkers, which were
combined in a qualitative and sequential predictive model with potential to improve the differential diagnosis of
pneumococcal, meningococcal and enteroviral meningitis. Moreover, we present the first evidence of the possible
implication of Kallikrein-kinin system in the pathophysiology of bacterial meningitis.
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Background
Meningitis is characterized by the inflammation of the
leptomeningeal membranes that surround the brain and
spinal cord [1-3]. Meningitis can be classified as aseptic
or bacterial [1]. The term “aseptic meningitis” refers to
meningeal inflammation without evidence of causative
bacterial infection [4], which can be caused by viruses,
fungi or chemical agents. Over 80% of all cases of viral
meningitis are caused by enteroviruses, and present a
benign clinical course being rarely associated with bad
outcome [4,5]. As opposite, bacterial meningitis is char-
acterized by an exacerbated inflammatory response in
the central nervous system (CNS), and its main causa-
tive agents are Streptococcus pneumoniae e Neisseria
meningitidis [1]. Bacterial meningitis is one of the 10
leading causes of death due to infectious diseases world-
wide [6], and about 10% patients die within 24-48 h of
the onset of symptoms. Long-term neurological sequelae
occurs in 10-20% of survivors [6]. Brain damage in
meningitis is due to a complex interplay between pro-
ducts released by the pathogens, such as pneumolysin,
cell wall degradation products, and DNA, and the exacer-
bated host inflammatory response with the recruitment
of neutrophils to the subarachnoid space. Activated neu-
trophils release many potentially cytotoxic agents includ-
ing oxidants that can cause lipid peroxidation, DNA
strand breakage, or matrix metalloproteinase (MMP)
activation (reviewed in [7]).
Early clinical findings of meningitis are usually unspeci-
fic, which sometimes impairs the diagnosis. In addition,
patients in the early stage of the disease or pre-treated
with antibiotics may have normal or inconclusive cyto-
chemical findings in the cerebrospinal fluid (CSF)[8-10].
Definitive diagnosis is usually established after CSF or
blood culture, and/or detection of bacterial antigens by
immunological tests, which may take longer than the
therapeutic window. Thus, at present, the empiric treat-
ment with broad-spectrum antibiotics, in some cases
associated with the anti-inflammatory drug dexametha-
sone, is recommended to patients with suspected bacter-
ial meningitis [11]. However, dexamethasone has been
shown to aggravate neuronal apoptosis in the dentate
gyrus of the hippocampus of animal models of bacterial
meningitis [12,13]. Therefore, there is a need for novel
robust and specific laboratory parameters to support
early and accurate differential diagnosis of meningitis, a
pre-requisite to the clinical decision for the appropriate
therapeutic approach.
This study aimed at identifying CSF protein markers
of the host response to the most prevalent forms of bac-
terial and enteroviral meningitis, as well as to disclose
putative novel therapeutic targets to prevent mortality
and morbidity associated with the malignant forms of
this disease. Using 2-dimensional gel electrophoresis
(2D-PAGE) and mass spectrometry (MS), four candidate
biomarkers were identified and combined in a qualita-
tive predictive model for the differential diagnosis of
pneumococcal, meningococcal and enteroviral meningi-
tis. Moreover, pathway analysis of the disease-specific
proteome signatures unveiled pathways and biological
processes involved the pathophysiological mechanisms
leading to brain damage in bacterial meningitis. Putative
novel therapeutic targets are proposed.
Results
2D PAGE qualitative analysis and protein identification
Qualitative comparison of the CSF proteome of the
groups with pneumococcal, meningococcal, and entero-
viral meningitis to each other, and to the control group
disclosed aetiology-specific spots characteristic of each
form of meningitis (Additional Figures 1, 2, 3, 4, Addi-
tional files 1, 2, 3, 4; Additional Tables 1 - 3, Additional
files 5, 6, 7).
Of the 695 protein spots subjected to mass spectrome-
try, 553 (80%) were identified, corresponding to 117 dis-
tinct proteins (Additional Table 4 Additional file 8).
Because we targeted the host proteome, at least part of
the non-identified spots in the 2D gels may be microbial
proteins. Twenty identified proteins occurred in the
intersection subsets of pneumococcal, meningococcal, or
enteroviral meningitis. However, most of the aetiology-
specific spots disclosed by comparing the 2D PAGE gels
were ruled out as potential biomarkers after identification
by mass spectrometry, since the same corresponding pro-
tein occurred in other positions of the gels (Additional
Tables 1 - 3, Additional files 5, 6, 7). These changes in
the migration properties of proteins at 2D PAGE gels
may be explained by alternative splicing, or by posttran-
slational modifications. As a consequence, only the
aetiology-specific spot of the intersection subset of
patients with meningococcal meningitis corresponding to
kininogen-1 was eligible to integrate the qualitative pre-
dictive model for differential diagnosis of meningitis. Six
non aetiology-specific spots belonging to the intersection
subsets of pneumococcal, and/or meningococcal, and/or
enteroviral meningitis (corresponding to complement
C3, c-reactive protein, and apolipoprotein A-I) proved to
be informative to the predictive model.
Predictive model for differential diagnosis of meningitis
A qualitative and sequential predictive model was pro-
posed to differentiate pneumococcal from meningococcal
meningitis and bacterial from enteroviral meningitis or
controls. The qualitative predictive model consists of three
nodes, each one related to the presence or absence in the
CSF of at least one of four putative protein biomarkers. At
the first node, the presence of Apolipoprotein A-I indi-
cates patients with bacterial or enteroviral meningitis.
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At the second node, the presence of C-reactive protein,
and complement C3 in the CSF are associated with the
diagnosis of bacterial meningitis, and their absence points
to enteroviral meningitis. Finally, at the third node, the
presence of kininogen-1 is associated with meningococcal
meningitis, and its absence, with pneumococcal meningitis
(Table 1 and Figure 1).
Subcellular localization of proteins
The subcellular localizations of the identified proteins
were predicted using the web version of the SherLoc 2
software (http://abi.inf.uni-tuebingen.de/Services/Sher-
Loc2). As expected, most proteins identified in the
union sets of the groups of patients with meningitis
were predicted to be located in the cytoplasm (46%) or
at the extracellular space (45%). However, about 10% of
these proteins were predicted to be located in the
nucleus (3%), plasma membrane (4%) or mitochondria
(2%). It is conceivable that these proteins were released
into the CSF as a result of membrane rupture and cell
death triggered by the inflammatory process. As oppo-
site, the proteins belonging to the intersection subsets of
groups of patients with meningitis were predicted be
only extracellular (71%) or cytoplasmatic (29%), support-
ing the idea that they may play a role in the pathophy-
siological processes of host response to the infection of
the CNS.
Pathway analysis
The canonical pathway “Blood coagulation_Blood coagu-
lation” was associated with meningococcal meningitis
(P value: 6.38 × 10-6). The cellular process “Inflamma-
tion_IL-6 signalling” was associated with meningococal
and enteroviral meningitis (P values< 10-6), but much
more strongly associated with pneumococcal meningitis
condition (P value: 1.07 × 10-13), while the “Inflamma-
tion_Kallikrein-kinin system”, was associated only with
meningococcal meningitis (P value: 1.7 × 10-7).
Discussion
This is the first study to compare the CSF proteome
profiles of patients with pneumococcal, meningococcal,
or enteroviral meningitis and that of individuals without
infection in the CNS or neurodegenerative or psychiatric
diseases. We analysed individually the CSF samples of
24 subjects with pneumococcal, meningococcal, or
enteroviral acute meningitis and controls without infec-
tion in the CNS or neurodegenerative or psychiatric dis-
eases. This conservative strategy added confidence to
our results since they represent the consensus of each
group formed by six patients of both sexes, with differ-
ent ages, and living in different areas of the northeast
and southeast Brazil. Another level of confidence came
from the proteins subcellular location prediction. The
fact that all proteins belonging to the intersection sub-
sets of the groups of patients with meningococcal, pneu-
mococcal or enteroviral meningitis were predicted to be
only extracellular (71%) or cytoplasmatic (29%) supports
the idea that they may play a role in the pathophysiolo-
gical processes of host response to the infection of the
CNS.
We selected four proteins of the host inflammatory
response to create a qualitative and sequential predictive
model for differential diagnosis of meningococcal, pneu-
mococcal and enteroviral acute meningitis. Evidences of
the diagnostic potential of three of these biomarkers have
already been published. For instance, the concentration
of apolipoprotein A-I in the CSF of patients with menin-
gitis increased in the acute phase of the disease, returning
to basal concentration in the convalescent phase. In
patients with other neurological diseases, the CSF levels
Table 1. Group distribution of the proteins selected for composing the qualitative predictive model for differential
diagnosis of meningitis
Uniprot Genbank Definition ∩ PM ∩ MM ∩ VM U PM U MM U VM U Ctrl
P02647 90108664 Apolipoprotein A-I 1 1 1 1 1 1 0
P02741 1942435 C-reactive protein 1 1 0 1 1 0 1
P01024 179665 Complement C3 1 1 0 1 1 0 1
P01042 4504893 Kininogen-1 0 1 0 0 1 0 0
∩ = intersection subset; U = union set; MP = pneumococcal meningitis; MM = menigococcal meningitis; MV = enteroviral meningitis; Ctrl: control; 1 = present; 0
= absent.
Figure 1 Predictive model for the differential diagnosis of
acute pneumococcal, meningococcal, and enteroviral
meningitis. PM = pneumococcal meningitis; MM = meningococcal
meningitis; VM = enteroviral meningitis; CTRL = control.
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of apolipoprotein A-I remained in the same range as in
controls [14]. Our results also agree with other works
reporting high concentrations of complement C3 in the
CSF of patients with bacterial meningitis compared to
patients with enteroviral meningitis and controls without
infection in the CNS [15,16]. Besides, several studies
have demonstrated the existence of increased levels of
C-reactive protein in cerebrospinal fluid and serum of
patients with bacterial meningitis compared with patients
with viral meningitis and control subjects [17-20]. How-
ever, there is no indication in the literature of the use of
apolipoprotein A-I, complement C3 and protein C-reac-
tive for differentiation between patients with acute bac-
terial meningitis, patients with enteroviral meningitis,
and individuals without infection in the CNS. In addition,
our results point to kininogen-1 as a potential biomarker
to differentiate between meningococcal and pneumococ-
cal acute meningitis. This is the first report of increased
CSF levels of kininogen-1 in patients with meningitis.
The putative role of this protein in the host response to
meningococcal meningitis is discussed below.
Our work is not the first attempt to investigate the
CSF proteome of patients with meningitis. Jesse et al
[21] had already performed comparative proteomic ana-
lysis using pools of CSF samples from groups of patients
with viral or bacterial meningitis, the latter group
included four different etiologic agents, namely: N.
meningitidis, S. pneumoniae, Staphylococcus aureus and
Listeria monocytogenes). These authors proposed six
proteins as candidate markers for the differential diag-
nosis of bacterial and viral meningitis, three of them
were also identified in the present study (haptoglobin,
fibrinogen b chain and prostaglandin D synthase). How-
ever, in the present study, these proteins occurred spar-
sely in the union sets of the groups of patients with
different forms of meningitis (data not shown), and
therefore, were ineligible as candidate biomarkers for a
qualitative model for differential diagnosis. In another
work, Goonetilleke et al [22] compared the proteome of
pools of CSF samples from control individuals with
those from patients who died due to pneumococcal
meningitis and survivors. These authors reported more
than 2,400 proteins differentially expressed as a result of
meningitis. Among the proteins found by Goonetilleke
et al, 26% were also identified in our study, and a com-
mon marker of meningitis was selected, namely the
complement C3. This protein had its expression level
decreased in patients who died due to pneumococcal
meningitis. The other proteins identified by Goonetilleke
et al and also detected in the present study occurred
sparsely in the union sets of patients with pneumococ-
cal, meningococcal or viral meningitis and thus, were
not considered as potential biomarkers.
Previous works have investigated the CSF levels of
inflammatory cytokines and chemokines in patients with
meningitis, such as IL-6, IL-1b, TNF-a, IL-10, chemo-
kines of the CXC family (IL-8) and growth factors using
immunoenzymatic methods [23-30]. None of these pro-
teins were detected in the present study using 2D PAGE
followed by mass spectrometry. This may be explained
by the relative low sensitivity of the 2D PAGE method
compared to immunologic methods used in the above
mentioned works. However, it is indeed the relative low
sensitivity of the 2D PAGE that ensures the robustness of
our results, i.e. the qualitative differences detected in the
proteomes of the investigated groups are probably due to
marked differences in the CSF concentrations of these
proteins as part of the pathogen-specific host responses.
Consequently, the definition of concentration cut off
points for the development of diagnostic kits using more
sensitive platforms such as ELISA, latex agglutination,
etc., should be facilitated by the magnitude of the differ-
ences in the concentrations of the selected biomarkers in
the CSF of patients with pneumococcal, meningococcal,
or enteroviral acute meningitis.
In order to shed light on the pathophysiological
mechanisms underlying the distinct outcomes asso-
ciated with the malign or benign forms of meningitis,
we submitted the disease-specific proteome signatures
to a pathway analysis using the software MetaCore
from Thompson Reuters. Not surprisingly, blood
coagulation was the canonical pathway most strongly
associated with meningococcal meningitis. Indeed, acti-
vation of coagulation and attenuation of fibrinolysis in
the CSF are important features of bacterial meningitis
and may contribute to brain infarction [31]. Also, as
expected, IL-6 signalling-mediated inflammation was
the cellular process most strongly associated with
pneumococcal meningitis. IL-6 contributes directly to
blood brain barrier (BBB) permeability and boosts
intracranial pressure and cerebral oedema in meningitis
[32,33]. Nonetheless, pathway analysis unveiled an
unexpected association between the kallikrein-kinin
system (KKS) and meningococcal meningitis. Kinino-
gen-1, the forth biomarker of the predictive model
developed in this study is a constituent of the kallik-
rein-kinin system (KKS). Kininogen is a kinin precursor
which binds to two receptor types, B1 and B2. While
the B2 receptor is constitutively expressed in various
cell types, including endothelial cells, the B1 receptor
is inducible by proinflammatory agents, such as IL-1b,
in pathophysiological conditions [34-36]. Both recep-
tors are members of the G protein-coupled receptors
subfamily [37] that, by binding to Gai and Gaq
families could regulate vascular processes, including
the production of nitric oxide (NO) [35,36]. NO
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production via endothelial nitric oxide synthase (eNOS)
allows B2-mediated regulation of blood pressure and
maintains the normal endothelial barrier [38,39]. As
opposite, in inflammatory conditions, the endothelial
cells can express inducible nitric oxide synthase (iNOS)
for NO production under cytokines stimulation, such
as IL-6, IL-1b and IFN-g. Although poorly understood,
it is known that the NO production by iNOS can be
also mediated by a B1 receptor in a process involving
extracellular-regulated kinase (ERK) [40]. Martins et al
[41] showed that the B2 kinin receptor has protective
effects in the CNS, whereas the B1 receptor has toxic
effects in this system. The stimulation of the B2 recep-
tor has preserved the integrity of hippocampal pyrami-
dal neurons against N-methyl-D-aspartate (NMDA)
receptor-mediated excitotoxicity. While the B2 receptor
blocking resulted in exacerbated brain damage in ani-
mal models of cerebral ischemia, the B1 receptor inac-
tivation has promoted protection against myocardial
and cerebral oedema in postischemic mice [42]. Thus,
the protective role of KKS system appears to be prefer-
entially associated with the B2 receptor, which regu-
lates blood pressure, reduces the BBB permeability and
decreases the release of pro-inflammatory cytokines
[35,42,43]. In bacterial meningitis, the percentage of
cases that progress to neurological sequelae ranges
from 16 to 38% in pneumococcal meningitis and from
3 to 21% in meningococcal meningitis [44-46]. One
possible explanation for the relatively lower incidence
of neurological sequelae in meningococcal meningitis
could be the activation of the KKS system that might
provide a neuroprotective effect in the brain by redu-
cing the vascular permeability and brain oedema.
Conclusions
The host response to the invasion of the CNS by bacter-
ial and viral pathogens leads to aetiology-specific pro-
teome signatures in the CSF. Protein biomarkers with
potential to improve the differential diagnosis as well as
putative therapeutic targets for adjunctive therapy were
predicted by comparing the CSF proteomes of groups of




This project was conducted according to the principles
expressed in the Declaration of Helsinki and was approved
by the Brazilian Council for Research Ethics (registry num-
bers 25000.140699/2005-93 and 25000.199054/2008-18).
All patients or their legal guardians received written infor-
mation concerning the study and gave written informed
consent for participation.
Patients, and CSF samples pre-treatment
The cohort comprised six patients for each form of
meningitis investigated, namely pneumococcal, menin-
gococcal, and enteroviral meningitis, and six individuals
without infection in the CNS, neurodegenerative, or psy-
chiatric diseases. These 24 patients had been admitted at
Hospital Giselda Trigueiro (Natal/RN) or Children’s
Hospital João Paulo II - FHEMIG (Belo Horizonte/MG).
Cerebrospinal fluid (CSF) samples were collected by
lumbar puncture before patients received any antibiotics
or anti-inflammatory drug and were kept at 4°C. No
more than six hours after puncture, CSF samples were
centrifuged for 10 minutes at 5,000 rpm, and the super-
natants were frozen at -20°C for up to one week and
then at -80°C until further analysis.
Patients with bacterial meningitis had pneumococci, or
meningococci in CSF, or blood specimens detected by cul-
ture, Gram-staining, and/or latex agglutination test. These
patients showed CSF white blood cell counts greater than
100 cells/mm3 being more than 50% neurophils. Patients
with enteroviral meningitis had pleocytosis characterized
mostly by mononuclear cells in the absence of detectable
bacterial pathogen. Furthermore, RNA of enterovirus was
detected in CSF by real time PCR as previously described
[47]. One patient with viral meningitis had mild pleocytosis
and no meningeal signs at the time CSF sample was col-
lected, but tested positive for enterovirus at real time PCR.
The control group was formed with individuals who under-
went lumbar puncture because of suspected of meningitis,
but have a normal CSF profile, spontaneous relief of symp-
toms. Additional details of the patients are shown in
Table 2. CSF samples with more than 250 red blood cells/
µL suggestive of puncture accident were excluded.
Proteins in aliquots of 300 µL of CSF were precipi-
tated with acetone (Merck KGaA, Dramstadt, Germany),
the pellets were ressuspended in 15µL ultrapure water
and the volumes were adjusted to 100 µL with PBS buf-
fer. These 3X concentrated protein solutions were
applied to the columns provided with the Albumin &
IgG Depletion SpinTrap kit (GE Healthcare, Uppsala,
Sweden) to deplete overabundant proteins. The proteins
in the whole volumes eluted from the columns (300 µL)
were precipitated again with acetone and solubilized in
50 µL of IEF rehydration buffer [8 M Urea, 2 M
Thiourea, 4% CHAPS, 0.0025%]. Protein concentrations
were assessed using the Bradford assay [48]. Protein
degradation was monitored in silver stained 1D PAGE
gels before and after albumin and IgG depletion. None
of the 24 samples showed signs of protein degradation.
2D-gel electrophoresis, imaging, and qualitative analysis
Two 2D-gels were run per each subject. Per each group, a
total of 12 gels were produced, comprising six individuals
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and their technical replicates. The volume containing
0.5 μg of protein was diluted in IEF rehydration buffer
[8 M Urea, 2 M Thiourea, 4% CHAPS, 0.0025% bromo-
phenol blue, 65 mM DTT and 1% BioLyte 3-10 buffer
100 × (Bio-Rad, Hercules, CA)] to a final volume of
125 µl. After homogenization under continuous agitation
for 1 hour at room temperature, the samples were centri-
fuged at 16,000 × g for 30 min. The supernatants were
loaded onto 7 cm IPG strip 3-10NL pH range (Bio-Rad)
by in-gel sample rehydration. Isoelectric focusing was
carried out in a Protean IEF Cell (Bio-Rad) at 20°C and
50 µA/strip. Passive rehydration was performed for
4 hours, followed by active rehydration at 50 V for
12 hours, and focalization at 500 V for 30 min, followed
by 1,000 V for 30 min, 4,000 V for 1 hour and 4,000 V up
to 16,000 V/h. The IPG strips were equilibrated in redu-
cing buffer (6 M Urea, 30% glycerol, 2% SDS, 50 mM
Tris-HCl pH 8.8, 0.001% bromophenol blue and 130 mM
DTT) for 10 min, and in alkylating buffer containing
135 mM iodoacetamide for a further 10 min. The IPG
strips and molecular weight standard were placed on top
of 12% SDS-PAGE gels and sealed with 0.5% agarose.
The second dimension electrophoretic protein separation
was carried out using a Mini-Protean III (Bio-Rad) under
60 V constant voltage for 10 min, and then under 100 V
until the dye front reached the bottom of the gel. The
Broad Range Molecular Weight (Bio-Rad, Hercules CA)
was used as molecular marker. After electrophoresis, gels
were stained by silver nitrate.
The 2D-gels were imaged using a GS-800 densit-
ometer (Bio-Rad). The PDQuest software version 8.0.1
(Bio-Rad) was used to display protein spots in the 2D-
gels, to create protein maps, and to perform qualitative
comparative analysis, i.e. comparing the protein maps of
patients within the same group to identify the spots
belonging to the union set, or to the intersection subset
of the group. The union set is defined as the ensemble
of all spots observed in at least one of the 12 gels of the
six subjects in a given group, while the intersection sub-
set includes only the spots present in at least 11 out of
the 12 gels of the group. Spots in the intersection sub-
sets were considered the most representative of the
respective groups.
Protein identification by mass spectrometry
In order to obtain enough protein for mass spectrome-
try, 2D gels were prepared with pooled CSF samples of
three patients with pneumococcal, meningococcal, or
enteroviral meningitis, randomly selected from those
used in the 2D PAGE described above. For each group
of patients, three 2D gels were made containing 10, 40
and 100 μg protein, respectively, under the same condi-
tions described above, but stained with Coomassie blue.
Protein spots from the 2D PAGE were manually excised
from the Coomassie blue stained gels and subjected to
in-gel tryptic digestion. The resulting digest was ana-
lysed by matrix-assisted laser desorption/ionization-time
of flight (MALDI-ToF-ToF) mass spectrometry using
the analyser 5800 Proteomics (AB Sciex, Framingham,
MA). The peptides were co-crystallized with 0.3 μl
matrix of a-cyano-4-hydroxycinnamic acid (Sigma-
Aldrich Inc., Saint Louis, MO) in 0.1% trifluoroacetic
acid, and 50% acetonitrile directly on the MALDI plate.
The MS and MS/MS data analysis were collected using a
laser with an iteration rate of 1 kHz. The number of
shots used was 2,000 for MS and MS/MS modes. The
twelve most intense peaks whose signal-to-noise ratio
was greater than two were selected as precursors to
acquire MS/MS, except the peaks arising from trypsin
autolysis or from the matrix. The MS external calibration
Table 2. Main characteristics of the groups of patients
PM MM VM Ctrl
Region *
Northeast 4 1 0 1
Southeast 2 5 6 5
Gender *
Female 1 4 3 2
Male 5 2 3 4
Age (years)
Median (range) 17.5 (2 - 36) 9.5 (<1 - 13) 6.0 (<1 - 8) 1.9 (<1 - 33)
CSF parameters
WBC 5,600 (240 - 1,199) 4,680 (72 - 19,500) 27 (2 - 500) 2 (1 - 9)
% PMN 91 (80 - 95) 94 (5 - 96) 20 (0 - 73) 34 (0 - 94)
Protein (mg/dL) ** 261 (110 - 474) 195 (66 - 461) 30 (18 - 38) 25 (20 - 35)
Glucose (mg/dL) ** 11 (1 - 71) 22 (2 - 53) 50.5 (47 - 68) 55 (40 - 72)
PM = pneumococcal meningitis; MM = meningococcal meningitis; VM = enteroviral meningitis; Ctrl = control; WBC - White blood cell count; PMN =
polymorphonuclear neutrophils; * = number of patients; ** median (range).
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mode was performed using a mixture of molecular mass
standards containing des-arg1-bradykinin (m/z = 904.47),
angiotensin I (m/z = 1296.69), Glu1-fibrinopeptide B (m/
z = 1570.68) and adrenocorticotropic hormone (ACTH)
(m/z = 3657.93) peptides. MS/MS spectra were externally
calibrated using the known masses of the fragments
observed in the MS/MS ion spectrum of Glu1-fibrino-
peptide B. The list of peptide and fragment mass values
generated by the mass spectrometer for each spot were
submitted to a MS/MS ion search using MASCOT
(Matrix Science, Boston, MA) to search in the Homo
sapiens section of the NCBI Reference Sequence Data-
base (NCBInr). The parameters used were: allowance of
two tryptic miss cleavages, peptide error tolerance of
±0.6 Da, MS/MS error tolerance of ±0.2 Da, peptide
charge +1 and variable modifications of methionine (oxi-
dation), cysteine (carbamidomethylation and propiona-
midation). To avoid random matches, only ions with
individual score above of the indicated by the MASCOT
to identity or extensive homology (p < 0.05) were consid-
ered for protein identification.
Bioinformatics analysis
The web version of the software SherLoc 2 (http://abi.
inf.uni-tuebingen.de/Services/SherLoc2) was used to pre-
dict the subcellular localization of the proteins identified
by mass spectrometry. SherLoc 2 integrates several types
of sequence-derived and text-based information, and is
suitable to a wide variety of eukaryotic organisms and
subcellular localizations [49].
Pathway analysis was performed with the aid of the
Enrichment Analysis (EA) workflow of the platform
MetaCore of Thompson Reuters. For the purpose of the
present study, the EA workflow can be defined as the
attempt to match Swissprot protein IDs of the union
sets of the groups with pneumococcal, meningococcal,
or enteroviral meningitis with protein IDs in functional
ontologies in MetaCore. The probability of a random
intersection between a set of IDs the size of the user’s
list with ontology entities is estimated in P value of
hypergeometric intersection. The lower P value means
higher relevance of the entity to the dataset. In this
study values smaller that 10-5 were considered signifi-
cant. Ontologies available for EA workflow include the
Canonical Pathway maps (signalling and metabolic maps
created by Thompson Reuters’ scientists by manual
curation of literature), Process Networks (cellular and
molecular processes defined and annotated by Thomp-
son Reuters scientists).
Additional material
Additional file 1: 2D gels of the six patients with pneumococcal
meningitis. Figure showing the images of one 2D PAGE gel of each
patient (panels A to F) from the group of pneumococcal meningitis.
MW = Molecular weight (Broad-range - BioRad).
Additional file 2: 2D gels of the six patients with meningococcal
meningitis. Figure showing the images of one 2D PAGE gel of each
patient (panels A to F) from the group of meningococcal meningitis.
MW = Molecular weight (Broad-range - BioRad).
Additional file 3: 2D gels of the six patients with enteroviral
meningitis. Figure showing the images of one 2D PAGE gel of each
patient (panels A to F) from the group of enteroviral meningitis. MW =
Molecular weight (Broad-range - BioRad).
Additional file 4: 2D gels of the six control individuals. Figure
showing the images of one 2D PAGE gel of each patient (panels A to F)
from the group of control individuals. MW = Molecular weight (Broad-
range - BioRad).
Additional file 5: Additional Table 1 - Distribution of the spots and
respective proteins of the intersection subset of patients with
pneumococcal meningitis. This table shows the distribution of the
spots and respective proteins of the intersection subset of patients with
pneumoccal meningitis
Additional file 6: Additional Table 2 - Distribution of the spots and
respective proteins of the intersection subset of patients with
menigococcal meningitis. This table shows the distribution of the spots
and respective proteins of the intersection subset of patients with
menigococcal meningitis
Additional file 7: Additional Table 3 - Distribution of the spots and
respective proteins of the intersection subset of patients with
enteroviral meningitis. This table shows the distribution of the spots
and respective proteins of the intersection subset of patients with
enteroviral meningitis
Additional file 8: Additional Table 4 - List of all protein identified by
mass spectrometry. This table contains the identification and description
of all proteins identified by mass spectrometry, as well as their distribution
in the union sets of the groups of patients with meningococcal,
pneumococcal or enteroviral meningitis, and the control group.
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